Bonus Biogroup Ltd (BONS)
Bonus Biogroup will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Bonus Biogroup is a clinical-stage biotechnology company focused on developing next-generation therapies.
Our mission is to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products that address severe conditions with limited treatment options.
We are developing BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage, both of which, we believe, may address significant unmet clinical and market needs.
Bonus Biogroup Ltd
| Country | Israel |
| Founded | 1981 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Dr. Shai Meretzki |
Contact Details
Address: Matam Advanced Technology Park, Building 20 Haifa, 3190501 Israel | |
| Phone | +972-73-206-7100 |
| Website | bonus-bio.com |
Stock Details
| Ticker Symbol | BONS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | ILS |
| CIK Code | 0001710531 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yosef Rauch | Chairman of the Board of Directors |
| Dr. Shai Meretzki | Chief Executive Officer, Director |
| Meital Enbar | VP Finance |
| Dr. Dror Ben David | Chief Operations Officer |
| Gil Shapira | Director |
| Alon Ariel | Director |
| Margalit Assayag | Director |
| Benjamin Shafir | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | F-1 | Registration statement for certain foreign private issuers |
| Apr 10, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 27, 2025 | DRS | [Cover] Draft Registration Statement |